Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ACTI.ST
- Price
- 0.20
- Stock movement down
- -0.01 (-3.64%)
- Company name
- Active Biotech AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 237.67M
- Ent value
- 244.97M
- Price/Sales
- -
- Price/Book
- 169.76
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -2.77%
- 1 year return
- -16.76%
- 3 year return
- -24.18%
- 5 year return
- -25.00%
- 10 year return
- -21.42%
Last updated: 2025-08-27
DIVIDENDS
ACTI.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 169.76 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.23B |
| EPS (TTM) | -0.12 |
| FCF per share (TTM) | -0.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -1.60M |
| Operating income (TTM) | -42.30M |
| Net income (TTM) | -41.60M |
| EPS (TTM) | -0.12 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.20M |
| Net receivables | 4.40M |
| Total current assets | 10.70M |
| Goodwill | 0.00 |
| Intangible assets | 200.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 14.90M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 11.50M |
| Total liabilities | 13.50M |
| Shareholder's equity | 1.40M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -39.60M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -39.60M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -2971.43% |
| Return on Assets | -279.19% |
| Return on Invested Capital | -2971.43% |
| Cash Return on Invested Capital | -2828.57% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.20 |
| Daily high | 0.21 |
| Daily low | 0.19 |
| Daily Volume | 11.5M |
| All-time high | 130.62 |
| 1y analyst estimate | 0.50 |
| Beta | 1.45 |
| EPS (TTM) | -0.12 |
| Dividend per share | - |
| Ex-div date | 17 Apr 1998 |
| Next earnings date | 6 Nov 2025 |
Downside potential
Loading...
Downside potential data
| ACTI.ST | S&P500 | |
| Current price drop from All-time high | -99.85% | -2.53% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -92.10% | -11.04% |
| Avg time to new high | 3562 days | 12 days |
| Max time to new high | 7123 days | 1805 days |
COMPANY DETAILS
Marketcap
237.67M
Marketcap category
Small-cap
Description
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Employees
5
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The cider brand has added a high-contrast NaviLens QR code to its cans.
September 9, 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
September 9, 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
September 9, 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
September 9, 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
September 9, 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
September 9, 2025